Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy
Source abstract
Abstract
Photodynamic therapy (PDT) has attracted much interest for the treatment of cancer due to the increased incidence of multidrug resistance and systemic toxicity in conventional chemotherapy. Phthalocyanine (Pc) is one of main classes of photosensitizers for PDT and possesses optimal photophysical and photochemical properties. A higher specificity can ideally be achieved when Pcs are targeted towards tumor-specific receptors, which may also facilitate specific drug delivery. Herein, we develop a simple and unique strategy to prepare a hydrophilic tumor-targeting photosensitizer ATF-ZnPc by covalently coupling zinc phthalocyanine (ZnPc) to the amino-terminal fragment (ATF) of urokinase-type plasminogen activator (uPA), a fragment responsible for uPA receptor (uPAR, a biomarker overexpressed in cancer cells), through the carboxyl groups of ATF. We demonstrate the high efficacy of this tumor-targeting PDT agent for the inhibition of tumor growth both in vitro and in vivo. Our in vivo optical imaging results using H22 tumor-bearing mice show clearly the selective accumulation of ATF-ZnPc in tumor region, thereby revealing the great potential of ATF-ZnPc for clinical applications such as cancer detection and guidance of tumor resection in addition to photodynamic treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Porphyrin and Phthalocyanine Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT10.1016/j.jphotobiol.2009.04.001 ↗
2. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity10.1007/s10495-010-0479-7 ↗
3. Strategies for selective delivery of photodynamic sensitisers to biological targets10.1142/S1088424604000325 ↗
4. Synthesis and properties of photo-activable phthalocyanines: a brief overview10.1007/s10847-010-9918-x ↗
5. Photodynamic therapy in oncology10.1634/theoncologist.11-9-1034 ↗
6. Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy10.2174/092986707780830970 ↗
7. Development of phthalocyanines for photodynamic therapy10.1142/S1088424606000466 ↗
8. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer10.1200/JCO.2007.14.2364 ↗
9. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer10.1160/TH03-12-0798 ↗
10. Structure of human urokinase plasminogen activator in complex with its receptor10.1126/science.1121143 ↗
11. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy10.1074/jbc.M109.093492 ↗
12. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes10.1073/pnas.82.15.4939 ↗
13. Structural basis of interaction between urokinase-type plasminogen activator and its receptor10.1016/j.jmb.2006.08.063 ↗
14. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide10.1038/sj.emboj.7600635 ↗
15. Evolving role of uPA/uPAR system in human cancers10.1016/j.ctrv.2007.10.005 ↗
16. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor10.1002/ijc.22340 ↗
17. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis10.1093/jnci/91.10.869 ↗
18. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications10.1111/cpf.12037 ↗
19. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy10.1016/j.jconrel.2010.10.030 ↗
20. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles
21. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies10.7150/thno.6810 ↗
22. Receptor-targeted nanoparticles for in vivo imaging of breast cancer10.1158/1078-0432.CCR-08-3289 ↗
23. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand10.1016/j.bmc.2011.03.016 ↗
24. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase10.1016/S0021-9258(19)49691-9 ↗
25. Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells
26. Gold nanomaterials conjugated with indocyanine green for dual-modality photodynamic and photothermal therapy10.1016/j.biomaterials.2012.01.035 ↗
27. Synthetic pathways to water-soluble phthalocyanines and close analogs10.1016/j.ccr.2010.05.002 ↗
28. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator10.1016/j.pep.2006.05.005 ↗
29. Derivatizable phthalocyanine with single carboxyl group: synthesis and purification10.1016/j.inoche.2005.12.002 ↗
30. Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy10.1002/cmdc.201000042 ↗
31. Relationship between the photochemical properties and structure of porphyrins and related compounds
32. Enhanced photodynamic efficacy of zinc phthalocyanine by conjugating to heptalysine10.1021/bc3002997 ↗
33. Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity10.1371/journal.pone.0037051 ↗
34. Lack of detectable West Nile virus RNA in brains and kidneys of dogs and cats with immunohistological precipitates using virus-specific antibodies10.1016/j.vetmic.2008.05.007 ↗
35. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins10.1016/0014-5793(94)00674-1 ↗
36. Regulation of urokinase receptors in monocyte like U937 cells by phorbol ester phorbol myristate acetate10.1083/jcb.108.2.693 ↗
37. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol10.1016/S0021-9258(18)52382-6 ↗
38. Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA10.1128/MCB.00080-07 ↗
39. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types10.1158/1535-7163.MCT-06-0315 ↗
40. Regulated portals of entry into the cell10.1038/nature01451 ↗
41. Glycerol and galactose substituted zinc phthalocyanines. Synthesis and photodynamic activity10.1039/b817348f ↗
42. UPAR: a versatile signalling orchestrator10.1038/nrm977 ↗
43. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes10.1093/emboj/16.10.2610 ↗
44. Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis
45. A confocal microscopy study of the very early cellular response to oxidative stress induced by zinc phthalocyanine sensitization10.1016/j.freeradbiomed.2005.06.006 ↗
46. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
47. Stimulation of anti-tumor immunity by photodynamic therapy10.1586/eci.10.81 ↗
48. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy
49. Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial10.1002/lsm.20984 ↗
50. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent10.1007/s002800050979 ↗
51. Successful cutaneous delivery of the photosensitizer silicon phthalocyanine 4 for photodynamic therapy10.1111/j.1365-2230.2010.03989.x ↗
52. Liposome-mediated delivery of photosensitizers: localization of zinc (II)-phthalocyanine within implanted tumors after intravenous administration10.1111/j.1751-1097.1996.tb05670.x ↗
53. Photodynamic therapy and the development of metal-based photosensitisers10.1155/2008/276109 ↗
54. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser PHOTOCYANINE: ROS production, apoptosis, cell cycle arrest10.1016/j.ejca.2011.10.013 ↗
55. Optimal light dose and drug dosage in the photodynamic treatment using PHOTOCYANINE10.1016/j.pdpdt.2010.10.003 ↗
56. Structural identification and quality study on isomers of a novel anticancer photosensitiser photocyanine
57. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
58. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma10.1038/bjc.1997.63 ↗
59. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
60. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas